Context: Type 1 diabetes mellitus (T1DM) is associated with a disturbance of carbohydrate and lipid metabolism.
I
n pregnant women with type 1 diabetes mellitus (T1DM), endogenous insulin production is absent or minimal, thus requiring exogenous insulin for glycemic control and prevention of ketoacidosis (1) . In addition to disturbances of carbohydrate metabolism, T1DM is associated with changes in the content and composition of maternal lipids (2) . Whether T1DM also influences content and composition of fetal lipids in the umbilical circulation is currently unknown.
Maternal sources of fetal lipids include lipoproteinassociated triacylglycerols, phospholipids, and cholesterol esters, as well as free fatty acids (FAs). The current understanding of maternal lipid supply for the fetus involves the transfer of free FAs and free cholesterol, after which, both moieties are esterified in the fetal liver and packaged into lipoproteins (2) . Despite the presence of FA transporters in the syncytiotrophoblast (3), free FAs are likely to cross this membrane by diffusion (4, 5) .
Nonessential FAs can also be formed de novo from carbohydrates and acetate in the fetus under the control of fetal insulin (6, 7) . In normal circumstances, free FAs have a minor role in energy provision; however, they generally can serve as energy deposits in the neonatal period (6) .
Particularly important for the fetus are the essential FAs, i.e., long-chain polyunsaturated FA (LC-PUFAs) (8) .
One of those LC-PUFAs, docosahexaenoic acid (DHA), has a major role in the development of nervous system cells, and its cord blood concentrations are associated with psychomotor development at 6 months of age (9, 10) . In pregnant women, there is an increased maternalfetal transfer of essential over nonessential FAs (11, 12) .
The aim of the study was to investigate the impact of T1DM on materno-fetal levels of FAs. Specifically, we tested the hypothesis of whether T1DM alters the FA profiles of maternal blood, the umbilical vein, and artery blood.
Materials and Methods

Study population
This prospective study included a total of 60 pregnant women with singleton pregnancies who had either T1DM (T1DM group, n = 30) or were healthy (control group, n = 30). Pregnant women with T1DM were followed up at the Department of Obstetrics and Gynecology, Zagreb University Hospital Center, from 2012 to 2016. Study women had a T1DM duration of 5 to 10 years, were without diabetes complications, had a normal course of pregnancy, and delivered healthy, eutrophic newborns within the 25th to 75th birthweight percentile, according to weeks of pregnancy, sex, and parity (13) . Pregnant women with T1DM were on intensified insulin analogs therapy and had well-controlled glycemia. Healthy women underwent gestational diabetes (GDM) screening, according to International Association of Diabetes and Pregnancy Study Groups criteria, with 75 g oral glucose tolerance test between gestational weeks 24 and 34 (14) . Women with preterm delivery, multiple pregnancies, diabetic complications (retinopathy, nephropathy, neuropathy, and chronic hypertension), fetal chromosomal anomalies, or malformations were excluded from the study. Additional exclusion criteria were smoking by self-report, n-3 and n-6 FA supplementation, gestational hypertension/pre-eclampsia, and GDM. Gestational age was determined by the first day of last menstruation and verified by ultrasound examination between 6 and 10 weeks of gestation.
All pregnancies were terminated by elective Caesarean section (CS) between gestational weeks 39 and 40. The mothers fasted for at least 10 hours before the CS. Maternal blood glucose during delivery was maintained in the range of 4 to 5 mM by IV infusion of 500 mL 5% glucose with insulin. Pregnancies in mothers with T1DM were terminated by CS as a standard procedure, whereas in the control group, indications for CS were breach presentation, narrow pelvis, post-CS state, or CS on mother's demand. Maternal venous blood samples (5 mL) were collected during delivery. Umbilical cord blood was obtained during the CS, immediately after delivery but before the placenta was removed through puncture of the umbilical vessels. Blood was centrifuged immediately after collection, and the sera were stored at 280°C until analysis.
C-Peptide and leptin concentrations and HbA 1c percentage were determined in maternal and umbilical vein serum. Free FA concentrations were quantified in maternal and umbilical vein and arterial serum.
Ethical statement
The study was approved by the Ethics Committee of the Clinical Department of Obstetrics and Gynecology, Zagreb University Hospital Center, School of Medicine, University of Zagreb (No. 021-1/117A-2012). All women included in the study provided written, informed consent for themselves and their newborns.
Data collection
The following parameters were recorded: maternal height (centimeters) and weight (kilograms) measured before pregnancy; gestational weight gain as the difference between weight before pregnancy (self-reported) and at time of delivery; and prepregnancy body mass index (BMI; kilograms per square meter; BMI), calculated from prepregnancy values. Maternal HbA 1c was determined in each trimester in the T1DM group and between the 36th and 38th weeks of pregnancy in the control group. Neonatal birth weight (grams), birth length (centimeters), and 1 and 5 minute Apgar scores were measured.
Blood sample analyses
FA quantification
Total lipids were extracted by a mixture of chloroform/ methanol solvent, a method of increasing polarity, according to Folch et al. (15) . Heptadecanoic acid (C17:0) was used as the internal standard. FAs from lipid extracts were converted to methyl esters by trans-esterification with methanolic HCl (International Organization for Standardization standard). The FA profile was determined by gas chromatography-mass spectrometry on a Varian 3400 (Varian, Palo Alto, CA), equipped with a Saturn II ion trap mass spectrometer operating in the electron impact mode, as previously described (12) . The concentration of each FA (micrograms per milliliter) was quantified by comparing the area of the internal standard peak (C17:0) with the peak area surface of a single FA. The results are expressed as percent (micrograms per 100 mg FAs) of arachidonic acid (AA) and DHA.
Glucose, HbA 1c , C-peptide, and leptin quantification Glucose levels were quantified by the hexokinase method on a Cobas C301 analyzer, and HbA 1c levels in whole blood were measured by the Turbidimetric Inhibition Immunoassay on a Cobas C501 analyzer with reagents from the manufacturer (Roche, Basel, Switzerland). C-peptide concentration was determined by ELISA (C-peptide ELISA; Mercodia, Uppsala, Sweden). Serum leptin concentration was determined by ELISA (Quantikine Human Leptin Immunoassay; R&D Systems, Minneapolis, MN). Neonatal insulin resistance was calculated according to homeostasis model assessment 2 (HOMA2) (16), using software available online (http://software.informer.com/landing/).
Statistical analysis
Statistical analyses were performed with SPSS statistical package (release by SPSS version 24 software; IBM, Chicago, IL). Continuous variables are expressed as the means 6 SD or medians (25th to 75th percentile) for a skewed distribution, and qualitative variables are presented as frequencies and percentages. Between-group differences in normally distributed continuous variables were assessed with a t test. The Mann-Whitney U test was used for variables with a skewed distribution, and a x 2 -test was used for proportions. For repeated measurements of continuous data, the Wilcoxon signed-rank test was used. Pearson correlation coefficient (r) was used to assess linear dependence between normally distributed variables. Linear regression was performed between the concentration of total FAs in maternal and umbilical vein serum and between docosahexaenoic and arachidonic FAs. Data that were not normally distributed were log transformed before analyses. Regression with Spearman correlation coefficient (rs) was performed for non-normality data. Statistical tests were two sided. Statistical analyses were considered significant when P , 0.05.
Results
Maternal and neonatal characteristics
Women with T1DM and controls did not differ (P . 0.05) in maternal age, BMI, or gestational weight gain (Table 1) . Neonates did not differ in gestational age at delivery, neonatal birth weight, or Apgar scores at 1 and 5 minutes. Neonates born to mothers with T1DM were shorter (P = 0.001) and thus, had a higher ponderal index (P , 0.001) compared with control group neonates. The HbA 1c values in the T1DM group dropped from 6.6% to 5.9% from the first to the third trimester (P = 0.022) but were still higher (P , 0.001) than in the control group (4.8%; Table 1 ).
Glucose, C-peptide, leptin, glucose levels, and insulin resistance in maternal and neonatal blood Maternal C-peptide concentration was higher (P = 0.007) in the control group than in the T1DM group (Table 1) . Women with T1DM had median C-peptide levels of 235.5 (interquartile range (94 to 554.8) pM, indicating that their b-cell function and endogenous insulin production were, in part, preserved. Maternal plasma glucose and leptin concentrations were similar in both groups. In the neonates, the umbilical cord vein concentrations of C-peptide (P , 0.001) and leptin (P , 0.001), as well as HOMA2 insulin resistance (P = 0.015), were higher in the T1DM group, whereas plasma glucose concentrations were similar in both groups (Table 1) .
FAs in maternal serum
The total FA concentration in serum of women with T1DM did not differ significantly (P = 0.074) when compared with the control group ( Table 2) . Although the concentration of saturated FAs (SFAs) in mothers with T1DM was not significantly different from controls (P = 0.071), the percentage of SFAs was significantly lower in T1DM than in the control group (34.8% vs 37.6%, P = 0.006). The concentration of both monounsaturated FAs (MUFAs) and PUFAs was significantly higher in serum of women with T1DM compared with controls (P = 0.016 and P = 0.027, respectively). However, the percentage of MUFAs and PUFAs was not significantly different between the groups (Table 2) .
FAs in umbilical vein serum
In umbilical vein serum, the concentration of total FAs, SFAs, MUFAs, and PUFAs was higher in T1DM compared with controls ( Table 2 ). The percentage of SFAs in umbilical vein was lower in the T1DM group (34.9% vs 44.3%, P = 0.002). In contrast, the percentage of MUFAs was higher in T1DM (31.9% vs 19.9%, P = 0.002), whereas the percentage of PUFAs did not differ (32.8% vs 31.4%, P = 0.53; Table 2 ).
FAs in umbilical artery serum
In umbilical artery serum, the concentration of total FAs, MUFAs, and PUFAs was higher in T1DM when compared with the controls (Table 2) . Compared with controls, the concentration of SFAs and the percentage of SFAs were lower in T1DM (201.8 vs 229.9, P 5 0.011; 34.7% vs 44.0%, P , 0.001). The percentage of MUFAs did not differ between the two groups, whereas the percentage of PUFAs was higher in T1DM than in the control group (31.3% vs 28.8%, P = 0.008).
Comparisons of FAs between maternal and umbilical vein serum
The concentrations of total FAs, SFAs, MUFAs, and PUFAs were higher in maternal serum of both T1DM and control women when compared the corresponding umbilical vein serum (all P , 0.001; Table 2 ). In controls, maternal serum was less rich in SFAs compared with umbilical vein serum (37.6% vs 44.3%, P = 0.004), but this difference was not found in T1DM (34.8% vs 34.9%, P = 0.230). A lower percentage of MUFAs was found in maternal serum of T1DM (21.3% vs 31.9%) when compared with umbilical vein serum (P , 0.001), whereas in the control group, the percentage MUFAs was higher in maternal (20.3%) than in umbilical vein serum (19.9%, P , 0.001). A higher percentage of PUFAs was found in maternal serum than in umbilical vein serum in both groups (T1DM: 43.3% vs 32.8%; controls: 41.7% vs 31.4%).
Comparisons of FAs between umbilical vein and artery serum
In T1DM, the concentrations of total FAs, SFAs, MUFAs, and PUFAs were all significantly higher in umbilical vein compared with the corresponding umbilical artery serum, but the percentages were not different ( Table 2) .
In controls, total FA concentration was higher in umbilical vein serum compared with artery serum. No differences in the concentration of SFAs and MUFAs were found between umbilical vein and artery serum of controls. The PUFA concentration was lower in umbilical vein than in artery serum. The percentage of SFAs was not different between venous and arterial serum in controls, whereas the percentage of MUFAs and PUFAs was lower and higher, respectively, in umbilical vein than in artery serum.
FA profile in maternal, umbilical vein, and umbilical artery serum
In maternal vein serum, the concentrations of all particular FAs tended to be higher in T1DM, but only the concentrations of oleic (C18:1n-9), DHA (C22:6n-3), and linoleic acid (C18:3n-6) were significantly different from controls (Table 3) .
In the umbilical vein serum, the concentrations of all particular FAs, except myristic acid (C14:0), were significantly higher in the T1DM group compared with the control group.
In the umbilical artery serum, differences between T1DM and controls were smaller, and only concentrations for palmitoleic (C16:1n-7), oleic (C18:1n-9), linoleic acid (C18:3n-6), and AA (C20:4n-6) were higher in the T1DM group compared with the control group. The FA concentrations not higher in T1DM were palmitic acid (C16:0) and stearic acid (C18:0) in umbilical artery serum, and in addition, the percentage DHA was significantly lower in T1DM compared with controls (2.7% vs 3.4%, P = 0.02).
Correlation between maternal serum and umbilical vein serum of total FAs and among neonatal ponderal index, glucose, and insulin resistance (HOMA2)
Maternal and umbilical vein total FAs were correlated with Pearson correlation coefficient (r) (r = 0.685; P , 0.001; Fig. 1 ). Umbilical artery and umbilical vein total FAs were strongly correlated (rs = 0.883; P , 0.001).
Maternal glucose concentrations were strongly correlated with glucose in umbilical vein (rs = 0.763; P , 0.001; ( Table 4) .
Longer-term, higher maternal glucose levels, reflected in higher HbA 1c (percentage) levels, were correlated with neonatal ponderal index (rs = 0.507; P = 0.003). Ponderal index was positively correlated with both leptin (rs = 0.263; P = 0.043) and insulin resistance (HOMA2; rs = 0.526; P = 0.005) in umbilical cord blood. Both C-peptide (rs = 0.379; P = 0.003) and insulin resistance (HOMA2; rs = 0.456; P = 0.02) in umbilical cord blood were correlated to total FAs in umbilical artery serum.
Discussion
The current study compared FA concentrations and the FA profile in maternal and umbilical venous and arterial serum between well-controlled T1DM and control mothers. Adiposity, which is a confounder of lipid and FAs levels, was comparable in the mothers, as there was no between-group difference in BMI and gestational weight gain. Similar to other studies (17) , also, leptin levels did not differ between the two study groups.
The most important finding was that well-controlled T1DM affects the FA levels, mostly in the neonates, in which the levels of total FAs, as well as most of the SFAs, MUFAs and PUFAs, were elevated compared with healthy controls. Importantly, also, the cord blood concentrations of the essential FAs, and in particular of DHA, were higher in the T1DM neonates than in the controls. Total FA concentrations were not significantly different between pregnant T1DM with good metabolic control and healthy, nondiabetic women. Large variation in the data may have precluded significance, as the concentrations of some FAs and FA classes were significantly elevated in maternal serum in the women with T1DM compared with control women. Consistent with the present results, also in GDM pregnancies, maternal lipids did not differ from control pregnancies (18) .
T1DM effects on neonatal anthropometrics and hormones
The cord blood levels of C-peptide, leptin, and insulin resistance were also significantly higher in the T1DM group compared with the control group. T1DM, similar to GDM and T2DM, is a known factor that predisposes women to have hypertrophic newborns through an enhanced fetal glucose-insulin axis. This eventually leads to more fetal adipose tissue, as reflected by higher leptin levels (19, 20) . Although the placenta also produces leptin, almost all leptin is released into the maternal circulation (21), thus making its contribution to the circulating leptin pool in the fetus small. Insulin and leptin in the cord blood are correlated, especially in neonates in the highest birthweight category (22) .
Leptin increases with the amount of adipose tissue and regulates fetal weight. Hence, children born to diabetic mothers have higher cord blood leptin levels than those born to nondiabetic mothers. Our leptin results are consistent with previous studies (23). Although we have not directly measured neonatal fat mass or relative body fat, the positive correlation (rs = 0.263; P = 0.043) between leptin and ponderal index may suggest an increase in neonatal fat in the T1DM pregnancies.
The higher insulin resistance HOMA2 (P = 0.015) in neonates born to mothers with T1DM compared with control mothers is an important finding. Insulin resistance (HOMA2) correlated with the neonatal ponderal index. The higher insulin resistance in T1DM neonates is likely the result of the higher maternal glucose levels, reflected by higher HbA 1c values in the third trimester than in the controls, but effects of early hyperglycemia cannot be ruled out (24) . Interestingly, despite neonatal hyperinsulinemia in the T1DM neonates, their birthweight was not different from control neonates. However, the shorter stature in T1DM neonates, which is another important and unexpected finding, may be associated with reduced lean mass. Thus, T1DM appears to affect the lean and fat compartments disproportionally, although this must be verified by more direct measurements of body composition.
A shorter length of neonates born to mothers of diabetic pregnancies was already found in GDM (25) . In that study, the interpretation was offered that fetal FAs, through the transcription factor peroxisome proliferator-activated receptor-g, may drive mesenchymal stem cell differentiation to a more adipogenic than osteoblastic phenotype. Whereas this is speculative, the elevated cord blood levels of FAs, found here in T1DM, may support this notion, which certainly warrants further studies.
T1DM effect on neonatal FAs
In well-controlled T1DM, maternal FA levels were higher than in controls, although this did not reach statistical significance for each species. This was accompanied by higher concentrations of total FAs, SFAs, MUFAs, and PUFAs in the neonate. Steady-state levels are determined by the following: transplacental 
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Data presented are median and first and third quartiles. The Mann-Whitney U test was used to test significant differences between the two groups.
Wilcoxon signed-rank test (see footnotes). P values in bold are significant.
Abbreviations: MUFAs, monounsaturated FAs; SFAs, saturated FAs. a Maternal and umbilical vein serum concentration of total FAs in T1DM, P , 0.001.
b Maternal and umbilical vein serum concentration of total FAs in control, P , 0.001.
c Umbilical vein and umbilical artery serum concentration of total FAs in T1DM, P , 0.016.
d Umbilical vein and umbilical artery serum concentration of total FAs in control, P = 0.892.
e Maternal and umbilical vein serum concentration of SFAs in T1DM, P , 0.001.
f Maternal and umbilical vein serum concentration of SFAs in control, P , 0.001.
g Umbilical vein and umbilical artery serum concentration of SFAs in T1DM, P , 0.001.
h Umbilical vein and umbilical artery serum concentration of SFAs in control, P = 0.765. w Umbilical vein and umbilical artery serum concentration of PUFAs in T1DM, P , 0.001.
x Umbilical vein and umbilical artery serum concentration of PUFAs in control, P , 0.016. Essential FAs are important for normal fetal growth and development (27) . Transplacental transport of DHA, eicosapentaenoic acid (EPA), and AA occurs in several steps, from cell transmembrane transport through intracellular transport modulated by protein carriers to further passage through the cell membrane toward the fetus (8, 28) . In our previous study, we demonstrated that there was no difference in LC-PUFA n-3 percentage between T1DM and control groups of pregnant women and their fetuses (12) , which is in line with the results presented here. Our results differ from an earlier study that found lower percentage of AA and DHA in neonates born to mothers with T1DM (29) . Here, the levels of AA and DHA were higher in women with T1DM and significantly higher in their fetuses compared with their control counterparts ( Table 3 ). The major difference between the two studies is that we measured FA percentage in serum, whereas the lower AA and DHA percentage was found in neonatal phospholipids. This would suggest that T1DM modifies the incorporation of AA and DHA into phospholipids. Whether DHA concentrations in cord blood serum or in the phospholipid fraction are more relevant for neonatal development remains to be established, but it is pertinent that the brain DHA transporter major facilitator superfamily domaincontaining protein 2 transfers DHA in phospholipids across the blood brain barrier (30) .
The placenta is important for selective AA and DHA canalization from the mother to the fetus; the evidence is a high coefficient of correlation between AA and DHA in the maternal and the umbilical vein blood (Fig. 2) . The median maternal percent of AA (5.8%) and DHA (2.0%) in serum of mothers with T1DM was similar to the control group (AA, 5.9%; DHA, 1.8%). AA serves as a precursor of proinflammatory eicosanoids, whereas DHA is a precursor of anti-inflammatory resolvins and protectins (31) ; this could suggest a proinflammatory environment in T1DM neonates that is perhaps associated with hyperleptinemia. In a recent randomized controlled trial, we found that DHA supplementation stimulated the production of endogenous insulin in women with T1DM and was accompanied by lower C-peptide levels in the newborn (32) . In our study, neonates born by mothers with T1DM had an elevated AA/DHA + EPA ratio (median 4.1:1). This imbalance may be an indication of their increased risk to develop obesity later in life (33) . It may well be that a beneficial effect of DHA supplementation may lie in improving the neonatal glucose-insulin axis and perhaps indirectly also, in DHA uptake into the brain across the blood brain barrier. This may also indirectly decrease the risk for childhood obesity.
Strengths of the study
This study investigates FA profiles and FA concentration in T1DM in arterial and venous cord blood. We have combined the FA measurements with those of key hormones known to influence lipid and FA levels, i.e., insulin and leptin.
Cord blood was obtained with the placenta still in situ and the neonate not separated, reducing the influences of the postpartum period and allowing the results to represent the in vivo situation as closely as possible. As all women delivered by elective CS and were denied access to food, the levels of FAs and other parameters measured in umbilical serum were not influenced by mode of delivery or nutritional status of the women. The measurement of the arterial and venous cord blood is another strength. There has been only one study in GDM that also determined the FA profile in both arms of the umbilical circulation (34) . The combination of these measurements with concentrations of hormonal regulators in the umbilical cord allows conclusions about potential mechanisms that determine the neonatal FA profile, although these must be confirmed in larger studies and other populations. We must acknowledge some limitations: The small sample size precluded significance of higher maternal FA levels in mothers with T1DM. The study included only well-controlled women with T1DM. The results may be different, especially for neonatal outcomes, in poorly controlled T1DM or in women without residual b-cell function, because adaptive and protective placental mechanisms may become exhausted under more extreme metabolic conditions (35) .
Future studies should measure DHA levels in serum, as well as in the phospholipids of newborn cord blood, and test which of these two fractions is more important for brain development and cognitive function in the children born to T1DM pregnancies.
Conclusion
In conclusion, the levels of leptin, C-peptide, insulin resistance, total FAs, SFAs, MUFAs, PUFAs, DHA, and AA were significantly higher in T1DM umbilical vein serum compared with those in the control group.
